GlassScriptPhysician profile
Lillian Argent
NPI 1871968628
$32,982.50
in general payments reported to CMS, 2019-2025
22 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,819 · 2022: $7,988 · 2023: $9,771 · 2024: $5,137 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $2,358 · Food and Beverage: $801 · Consulting Fee: $650 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Travel and Lodging | $2,358.15 |
| Food and Beverage | $801.38 |
| Consulting Fee | $650.00 |
| Education | $115.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16,165.14 | 2021-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $10,706.32 | 2021-2024 | Enhertu |
| Seagen INC. | $2,378.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $519.13 | 2021-2022 | |
| Amgen INC. | $435.54 | 2021 | |
| Eisai INC. | $357.49 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $322.86 | 2021 | |
| Incyte Corporation | $314.42 | 2021-2022 | |
| Genzyme Corporation | $230.25 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $225.53 | 2021-2024 | Libtayo |
| Abbvie INC. | $225.14 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $216.32 | 2021 | |
| Glaxosmithkline, LLC. | $142.51 | 2021 | |
| Puma Biotechnology, INC. | $135.52 | 2021 | |
| Genentech USA, INC. | $121.94 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $116.48 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Astellas Pharma US INC | $95.85 | 2021 | |
| Merck Sharp & Dohme LLC | $74.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.20 | 2021 | |
| Celgene Corporation | $13.49 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Argent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.